The transmissible nature of communicable diseases is what sets them apart from other diseases modeled by health economists. The probability of a susceptible individual becoming infected at any one point in time (the force of infection) is related to the number of infectious individuals in the population, will change over time, and will feed back into the future force of infection. These nonlinear interactions produce transmission dynamics that require specific consideration when modeling an intervention that has an impact on the transmission of a pathogen. Best practices for designing and building these models are set out in this paper.
CaroJJBriggsAHSiebertUKuntzKM. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–1. Med Decis Making. 2012;32(5):667–677.
2.
RobertsMRussellLBPaltielADChambersMMcEwanPKrahnM. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–2. Med Decis Making. 2012;32(5):678–689.
3.
SiebertUAlagozOBayoumiAM. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3. Med Decis Making. 2012;32(5):690–700.
4.
KarnonJStahlJAlanBCaroJJMarJMöllerJ. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group–4. Med Decis Making. 2012;32(5):701–711.
5.
BriggsAHWeinsteinMCFenwickEALKarnonJSculpherMJPaltielAD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group–6. Med Decis Making. 2012;32(5):722–732.
6.
EddyDMHollingworthWCaroJJTsevatJMcDonaldKMWongJB. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–7. Med Decis Making. 2012;32(5):733–743.
7.
BrissonMEdmundsWJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making. 2003;23:76–82.
8.
BrissonMEdmundsWJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making. 2006;26:434–46.
9.
KimSYGoldieSJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008;26:191–215.
10.
RobertsTERobinsonSBartonPBryanSLowN; Chlamydia Screening Studies Group. Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling. Sex Transm Infect. 2006;82:193–200.
11.
KretzschmarMWallingaJ. Mathematical models in infectious disease epidemiology. In: KramerAKretzschmarMKrickenbergK, eds. Modern Infectious Disease Epidemiology. New York: Springer; 2009. p 209–21.
12.
AndersonRMMayRM. Infectious Diseases of Humans: Dynamics and Control. New York: Oxford University Press; 1991.
13.
JelinekT; TropNetEurop. Imported falciparum malaria in Europe: 2007 data from TropNetEurop. Euro Surveill. 2008;13:18895.
14.
LindsaySWHoleDGHutchinsonRARichardsSAWillisSG. Assessing the future threat from vivax malaria in the United Kingdom using two markedly different modelling approaches. Malar J. 2010;9:70.
15.
LipsitchMCohenTCooperB. Transmission dynamics and control of severe acute respiratory syndrome. Science. 2003;300:1966–70.
16.
LipsitchM. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis. 1999;5:336–45.
17.
LipsitchM. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci U S A. 1997;94:6571–6.
18.
BrissonMEdmundsWJGayNJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. 2003;70:S31–7.
19.
ClaesCReinertRRvon der SchulenburgJM. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur J Health Econ. 2009;10:25–38.
20.
BergmanAHjelmgrenJOrtqvistA. Cost-effectiveness analysis of a universal vaccination programme with the 7–valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Scand J Infect Dis. 2008;40:721–9.
21.
WalkerDBeutelsP; Initiative for Vaccine Research. WHO Guide for Standardization of Economic Evaluations of Immunization Programmes. Geneva: World Health Organization; 2008. Contract no. WHO/IVB/08.14. Available from: http://www.who.int/vaccines-documents/
22.
WelteRPostmaMLeidlRKretzschmarM. Costs and effects of chlamydial screening: dynamic versus static modeling. Sex Transm Dis. 2005;32:474–83.
23.
FismanDNSpainCVSalmonMEGoldbergM. The Philadelphia High-School STD Screening Program: key insights from dynamic transmission modeling. Sex Transm Dis. 2008;35:S61–5.
24.
GalvaniAPRelugaTCChapmanGB. Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum. Proc Natl Acad Sci U S A. 2007;104:5692–7.
25.
BrissonMEdmundsWJGayNJLawBDe SerresG. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect. 2000;125:651–69.
26.
BergeJJDrennanDPJacobsRJ. The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology. 2000;31:469–73.
27.
FineJDArndtKA. The TORCH syndrome: a clinical review. J Am Acad Dermatol. 1985;12:697–706.
28.
Centers for Disease Control and Prevention.Measles, rubella, and congenital rubella syndrome: United States and Mexico, 1997–1999. MMWR Morb Mortal Wkly Rep. 2000;49:1048–50.
29.
PanagiotopoulosTAntoniadouIValassi-AdamE. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ. 1999;319:1462–7.
30.
EdmundsWJBrissonM. The effect of vaccination on the epidemiology of varicella zoster virus. J Infect. 2002;44:211–9.
31.
BrissonMEdmundsWJGayNJMillerE. Varicella vaccine and shingles author reply. JAMA. 2002;287:2211–2.
32.
EdmundsWJMedleyGFNokesDJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med. 1999;18:3263–82.
33.
LipsitchMBergstromCTLevinBR. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc Natl Acad Sci U S A. 2000;97:1938–43.
34.
AdamHJRichardsonSEJamiesonFBRawtePLowDEFismanDN. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine. 2010;28:4073–8.
35.
HanageWPHuangSSLipsitchM. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis. 2007;195:347–52.
36.
SamoreMHLipsitchMAlderSC. Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations. Am J Epidemiol. 2006;163:160–70.
37.
JitMBrissonM. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics. 2011;29:371–86.
38.
KimSYGoldieSJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008;26(3):191–215.
39.
Van de VeldeNBrissonMBoilyMC. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine. 2010;28:5473–84.
40.
AjelliMGoncalvesBBalcanD. Comparing large-scale computational approaches to epidemic modeling: agent-based versus structured metapopulation models. BMC Infect Dis. 2010;10:190.
41.
Brooks-PollockECohenTMurrayM. The impact of realistic age structure in simple models of tuberculosis transmission. PLoS One. 2010;5:e8479.
42.
PerezLDragicevicS. An agent-based approach for modeling dynamics of contagious disease spread. Int J Health Geogr. 2009;8:50.
43.
BeutelsPScuffhamPAMacIntyreCR. Funding of drugs: do vaccines warrant a different approach?Lancet Infect Dis. 2008;8:727–33.
44.
van HoekAJMelegaroAGayNBilckeJEdmundsWJ. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine. 2012;30(6):1225–34.
45.
FossAMVickermanPTChalabiZMayaudPAlaryMWattsCH. Dynamic modeling of herpes simplex virus type-2 (HSV-2) transmission: issues in structural uncertainty. Bull Math Biol. 2009;71:720–49.
46.
JitMDemarteauNElbashaE. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Med. 2011;9:54.
47.
BrunhamRCPourbohloulBMakSWhiteRRekartML. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis. 2005;192:1836–44.
48.
VickersDMOsgoodND. Current crisis or artifact of surveillance: insights into rebound chlamydia rates from dynamic modelling. BMC Infect Dis. 2010;10:70.
HeijneJCAlthausCLHerzogSAKretzschmarMLowN. The role of reinfection and partner notification in the efficacy of chlamydia screening programs. J Infect Dis. 2011;203:372–7.
51.
van BovenMMooiFRSchellekensJFde MelkerHEKretzschmarM. Pathogen adaptation under imperfect vaccination: implications for pertussis. Proc Biol Sci. 2005;272:1617–24.
52.
FraserCRileySAndersonRMFergusonNM. Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci U S A. 2004;101:6146–51.
53.
AndersonRMMayRM. Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes. J Hyg (Lond). 1985;94:365–436.
54.
ZagheniEBillariFCManfrediPMelegaroAMossongJEdmundsWJ. Using time-use data to parameterize models for the spread of close-contact infectious diseases. Am J Epidemiol. 2008;168:1082–90.
55.
JohnsonAMMercerCHErensB. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet. 2001;358:1835–42.
56.
HalloranMELonginiIMJrStuchinerCJ. Assessing indirect, total, and overall effects. In: HalloranMELonginiIMJrStuchinerCJ, eds. Design and Analysis of Vaccine Studies. New York: Springer; 2010. p 271–312.
57.
SaccomaniMP. An effective automatic procedure for testing parameter identifiability of HIV/AIDS models. Bull Math Biol. 2011;73(8):1734–53.
58.
Pandemic Influenza Outbreak Research Modelling Team, FismanD. Modelling an influenza pandemic: a guide for the perplexed. CMAJ. 2009;181:171–3.
59.
MoghadasSMPizziNJWuJTamblynSEFismanDN. Canada in the face of the 2009 H1N1 pandemic. Influenza Other Respi Viruses. 2011;5:83–8.
60.
van RossumTGde MelkerHEHouwelingH. [Vaccines against human papillomavirus (HPV); between registration and implementation]. Ned Tijdschr Geneeskd. 2008;152:987–92.
61.
HalloranMEFergusonNMEubankS. Modeling targeted layered containment of an influenza pandemic in the United States. Proc Natl Acad Sci U S A. 2008;105:4639–44.
62.
HutubessyRHenaoAMNamgyalPMoorthyVHombachJ. Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal. BMC Med. 2011;9:55.
63.
MossongJHensNJitM. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5:e74.
64.
FentonKAKorovessisCJohnsonAM. Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection. Lancet. 2001;358:1851–4.
